… of the Indevus shares he owned in his personal brokerage account on May 30, 2008, after learning the U.S. Food and Drug Administration would delay the approval of Nebido, the company’s experimental testosterone replacement therapy . …
Original post:
Indevus VP Charged with Insider Trading | Securities Law News Blog